Development of Long-Acting Treatment Therapies to Open Up Exciting Opportunities in Hemophilia A and B Therapeutics Markets

Published Date : Apr 18, 2017

Albany, New York, April 18, 2017: has announced the addition of a report titled “Hemophilia A and B Therapeutics In Asia-Pacific Markets To 2022” to its offering. The report offers an in-depth insight into the major drivers, key restraining factors, emerging trends and opportunities, technological advances, regulatory landscape, market share and size of various segments, and competitive dynamics. The research reports highlights recent clinical studies that assess the efficacy of current treatments. The research study extensively profiles currently marketed therapies and takes a closer look at various pipeline products of leading biotech companies that are likely to open up lucrative avenues for market players.

The report highlights major clinical studies related with the development of late stage therapies and commercial positioning strategies of leading players. In addition, the report zeroes in on key licensing deals and co-development initiatives expected to considerably alter the competitive landscape in the coming years. The Asia Pacific hemophilia A therapeutics market is projected to reach U$699.1 mn by 2022 expanding at a CAGR of 6.7% from 2016 to 2022. During the same period, rising at a CAGR of 5.8%, the Asia Pacific hemophilia B therapeutics market is expected to reach U$112.9 mn by the end of the forecast period.

The research reports highlights first-in-class targets for hemophilia A and B that have enormous therapeutic potential in countries such as India, China, Australia, Japan, and South Korea. The increasing incidence of hemophilia A and B genetic disorders due to factor VIII deficiency and factor IX deficiency respectively has led to the advent of plasma-derived or recombinant methods, thereby propelling the Asia Pacific hemophilia B therapeutics markets. The need to counter the effect of inhibitors developed in patients after the initiation of replacement therapies has stimulated the demand for bypassing agents, such as factor VIIa, thereby fuelling the market.

For Sample Copy, click here:

The rise in uptake of recently approved therapies and the growing popularity of prophylactic therapies are expected to positively impact the market in the coming years. Furthermore, the marked shift from replacement to non-factor treatment therapies has opened up promising opportunities in the markets.

However, the high cost of advanced recombinant therapies in countries such as China and India has restrained their adoption. On the other hand, substantial unmet need in various emerging nations for treatments that prevent the development of inhibitors in patients with hemophilia is expected to open up exciting opportunities in the markets. In addition, the advent of late-stage pipeline treatment products is expected to give way to new revenue streams in the Asia Pacific hemophilia A and B therapeutics market over the forecast period.

Major players vying for a significant share in the hemophilia A and B therapeutics markets in Asia Pacific include Novo Nordisk, Octapharma AG, CSL Behring, Baxalta, Roche Holding AG, and Pfizer. The report extensively profiles the marketed products of leading companies and evaluates their impact on competitive landscape.

To order report Call Toll Free: 866-997-4948 or send an email on